Ironwood Pharmaceuticals, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000GBZ3J2
IRWD
Ironwood Pharmaceuticals, Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Drug Manufacturers—Specialty & Generic
NAME
Ironwood Pharmaceuticals, Inc.
ISIN
US46333X1081
TICKER
IRWD
MIC
XNAS
REUTERS
IRWD.OQ
BLOOMBERG
IRWD US
F&G:
35
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Fr., 25.04.2025
Ironwood Pharmaceuticals
US46333X1081
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced it reiterates its full year 2025 LINZESS U.S. net sales and total Ironwood revenue guidance and raises its adjusted EBITDA guidance. Ironwood p...
Ironwood Pharmaceuticals
Di., 22.04.2025
Ironwood Pharmaceuticals
US46333X1081
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present real-world data during the 2025 Digestive Disease Week® (DDW) meeting, taking place May 3-6 in San Diego, CA. Thes...
Ironwood Pharmaceuticals
Mo., 14.04.2025
Ironwood Pharmaceuticals
US46333X1081
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval of...
Ironwood Pharmaceuticals
Do., 27.03.2025
Ironwood Pharmaceuticals
US46333X1081
Ironwood Pharmaceuticals, Inc. (the “Company”) (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that it received a notification letter (the “Notice”) on March 21, 2025 from the Listing Qualifications Department of The Nasda...
Ironwood Pharmaceuticals
Do., 27.02.2025
Ironwood Pharmaceuticals
US46333X1081
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results and recent business performance.
“We believe that 2025 marks the beginning of a transformation f...
Ironwood Pharmaceuticals
Do., 20.02.2025
Ironwood Pharmaceuticals
US46333X1081
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) usi...
Ironwood Pharmaceuticals
Mi., 29.01.2025
Ironwood Pharmaceuticals
US46333X1081
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced a streamlined strategic focus on advancing and realizing the potential of apraglutide for the treatment of short bowel syndrome (“SBS”) patient...
Ironwood Pharmaceuticals
Di., 26.11.2024
Ironwood Pharmaceuticals
US46333X1081
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the com...
Ironwood Pharmaceuticals
Mi., 13.11.2024
Ironwood Pharmaceuticals
US46333X1081
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London.
A live webcast of Ironwood’s fireside chat will be ...
Ironwood Pharmaceuticals
Do., 07.11.2024
Ironwood Pharmaceuticals
US46333X1081
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance.
“LINZESS continued to deliver robust prescription demand growth in the third quarter,” said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. “LINZESS extended units and new...
Ironwood Pharmaceuticals
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
